Form 6-K Itau Unibanco Holding For: Apr 02
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of April 2015
Commission File Number: 001-15276
Itaú Unibanco Holding S.A.
(Exact name of registrant as specified in its charter)
Itaú Unibanco Holding S.A.
(Translation of Registrant’s Name into English)
Praça Alfredo Egydio de Souza Aranha, 100-Torre Itaúsa
04344-902 São Paulo, SP, Brazil
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F: x Form 40-F: o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes: o No: x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes: o No: x
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: o No: x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-___________________.
82-___________________.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Itaú Unibanco Holding S.A.
|
||||
(Registrant) | ||||
Date: April 2, 2015 | By: | /s/ Marcelo Kopel | ||
Name: | Marcelo Kopel | |||
Title: | Investor Relations Officer | |||
By: | /s/ Eduardo Mazzilli de Vassimon | |||
Name: | Eduardo Mazzilli de Vassimon | |||
Title: | Chief Financial Officer | |||
EXHIBIT INDEX
99.1
|
Announcement to the Market: Trading of Own Shares for Treasury Month: March 2015
|
Itaú Unibanco Holding S.A.
A Publicly Listed Company | CNPJ. 60.872.504/0001-23 |
Announcement to the Market
Trading of Own Shares for Treasury
Month: March 2015
1.
|
On November 18, 2004, in keeping with the best Corporate Governance practice, Itaú Unibanco Holding S.A. (“Itaú Unibanco”) voluntarily disclosed its “Operating Rules for the Trading of Own Shares for Treasury”(“Rules”).
|
2.
|
Item 2.1.3 of the “Rules” established the obligation to make monthly disclosure of the volumes of own shares traded on stock exchanges by Itaú Unibanco, and minimum, average and maximum prices.
|
3.
|
In this context, we wish to inform that duringMarch 2015, Itaú Unibanco acquired 2,000,000 preferred shares, the average acquisition price for which was R$ 34.07 (maximum price of R$ 34.41 and minimum of R$ 33.64).
|
4.
|
We would point out that these acquisitions relate to the share buy-back program, effective for December 16, 2014 until December 15, 2015, approved by the Board of Directors, authorizing the acquisition of up to 10.0 million of common shares and 50.0 million in preferred shares.
|
5.
|
Considering the said acquisition, it should be kept in mind that in the approved share buy-back program, we had already acquired 17,596,600 preferred shares at the average price of R$ 34.26 as shown in the following table.
|
Current Repurchase | Trading |
Prices – R$ per Share
|
||||
Program
|
Transaction
|
Volume
|
Minimum
|
Average
|
Maximum
|
|
Dec/14
|
1,000,000
|
34.13
|
34.75
|
35.07
|
||
|
Jan/15
|
|
11,000,000
|
33.12
|
34.13
|
34.81
|
Preferred Shares
|
Feb/15 |
Purchase
|
3,596,600 | 33.89 |
34.68
|
35.05
|
Mar/15 | 2,000,000 | 33.64 | 34.07 | 34.41 | ||
Total
|
17,596,600
|
33.12
|
34.26
|
35.07
|
6.
|
We would remind readers that historical data is available in the organization’s Investor Relations site (www.itau-unibanco.com/investor-relations).
|
São Paulo-SP, April 2nd, 2015.
MARCELO KOPEL
Investor Relations Officer
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ITAÚ UNIBANCO - Interactive Meeting 1Q24
- Webster Reports First Quarter 2024 EPS of $1.23; Adjusted EPS of $1.35
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!